In addition, POLE mutations were found to be significantly associated with responses to adjuvant therapy, and patients with POLE mutations receiving chemotherapy exhibited poorer overall survival (OS) (18), which may be due to the generation of many tumor neoantigens by POLE mutations, resulting in patient insensitivity to adjuvant therapy. This evidence concerns the gene POLE and neoplasm.